CAIV-T
Sponsors
MedImmune LLC
Conditions
HealthyHealthy Japanese Male AdultsInfluenza
Phase 1
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants
CompletedNCT00192348
Start: 2002-05-31End: 2002-12-31Target: 120Updated: 2021-09-13
Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults
CompletedNCT00224783
Start: 2002-08-31End: 2002-09-30Updated: 2012-01-26
Phase 2
Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)
CompletedNCT00111579
Start: 2005-05-31End: 2006-01-31Target: 52Updated: 2008-07-24
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children
CompletedNCT00192270
Start: 2000-10-31End: 2001-01-31Updated: 2012-03-06
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
CompletedNCT00192166
Start: 2002-10-31End: 2003-05-31Target: 1200Updated: 2008-12-08
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
CompletedNCT00192309
Start: 2001-09-30End: 2001-12-31Updated: 2012-02-14
Phase 3
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
CompletedNCT00192335
Start: 2004-07-31End: 2005-02-28Updated: 2007-11-27
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.
CompletedNCT00192400
Start: 2002-03-31End: 2002-11-30Target: 2160Updated: 2006-10-03
Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.
CompletedNCT00192426
Start: 2001-09-30End: 2001-12-31Target: 2400Updated: 2006-10-03
Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)
CompletedNCT00192361
Start: 1999-11-30Target: 200Updated: 2006-10-25
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)
CompletedNCT00192231
Start: 2001-04-30End: 2001-06-30Target: 120Updated: 2021-09-13
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers
CompletedNCT00192283
Start: 2000-09-30End: 2002-05-31Updated: 2009-04-10
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults
CompletedNCT00192192
Start: 2000-11-30End: 2000-12-31Target: 20Updated: 2021-09-13
Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older
CompletedNCT00217230
Start: 2001-04-30End: 2001-11-30Target: 3000Updated: 2006-10-03